Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm of study expected in second half of 2023MRT-2359 received Fast...
-
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the...
-
MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionDisclosure of...
-
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that...
-
– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors – – Progressed VAV1 Molecular Glue Degrader...
-
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the...
-
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company...
-
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers – – Novel and Proprietary AI/Machine Learning...
-
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that...
-
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5...